Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
RMTI's Cash to Debt is ranked higher than
98% of the 712 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.35 vs. RMTI: No Debt )
Ranked among companies with meaningful Cash to Debt only.
RMTI' s 10-Year Cash to Debt Range
Min: 0.01  Med: 26.74 Max: No Debt
Current: No Debt
Equity to Asset 0.72
RMTI's Equity to Asset is ranked higher than
65% of the 575 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.64 vs. RMTI: 0.72 )
Ranked among companies with meaningful Equity to Asset only.
RMTI' s 10-Year Equity to Asset Range
Min: -0.59  Med: 0.62 Max: 0.92
Current: 0.72
-0.59
0.92
F-Score: 6
Z-Score: 12.82
M-Score: -3.95
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -26.57
RMTI's Operating margin (%) is ranked lower than
85% of the 669 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.92 vs. RMTI: -26.57 )
Ranked among companies with meaningful Operating margin (%) only.
RMTI' s 10-Year Operating margin (%) Range
Min: -108.87  Med: -15.81 Max: 2.28
Current: -26.57
-108.87
2.28
Net-margin (%) -30.14
RMTI's Net-margin (%) is ranked lower than
86% of the 671 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.96 vs. RMTI: -30.14 )
Ranked among companies with meaningful Net-margin (%) only.
RMTI' s 10-Year Net-margin (%) Range
Min: -108.39  Med: -15.60 Max: 1.18
Current: -30.14
-108.39
1.18
ROE (%) -42.94
RMTI's ROE (%) is ranked lower than
86% of the 699 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.43 vs. RMTI: -42.94 )
Ranked among companies with meaningful ROE (%) only.
RMTI' s 10-Year ROE (%) Range
Min: -1304.41  Med: -33.13 Max: 6.43
Current: -42.94
-1304.41
6.43
ROA (%) -24.65
RMTI's ROA (%) is ranked lower than
85% of the 718 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.50 vs. RMTI: -24.65 )
Ranked among companies with meaningful ROA (%) only.
RMTI' s 10-Year ROA (%) Range
Min: -220.66  Med: -23.78 Max: 2.88
Current: -24.65
-220.66
2.88
ROC (Joel Greenblatt) (%) -568.75
RMTI's ROC (Joel Greenblatt) (%) is ranked lower than
89% of the 714 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 12.24 vs. RMTI: -568.75 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
RMTI' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2678.13  Med: -91.67 Max: 11.55
Current: -568.75
-2678.13
11.55
Revenue Growth (3Y)(%) -21.90
RMTI's Revenue Growth (3Y)(%) is ranked lower than
92% of the 548 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.80 vs. RMTI: -21.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
RMTI' s 10-Year Revenue Growth (3Y)(%) Range
Min: -23  Med: 1.70 Max: 36.8
Current: -21.9
-23
36.8
EBITDA Growth (3Y)(%) -30.10
RMTI's EBITDA Growth (3Y)(%) is ranked lower than
88% of the 494 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. RMTI: -30.10 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
RMTI' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -36.2  Med: -15.70 Max: 159.6
Current: -30.1
-36.2
159.6
EPS Growth (3Y)(%) -24.50
RMTI's EPS Growth (3Y)(%) is ranked lower than
81% of the 455 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. RMTI: -24.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
RMTI' s 10-Year EPS Growth (3Y)(%) Range
Min: 0  Med: -18.30 Max: 109.9
Current: -24.5
0
109.9
» RMTI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2013

RMTI Guru Trades in Q2 2013

Jim Simons 185,628 sh (New)
» More
Q3 2013

RMTI Guru Trades in Q3 2013

Jim Simons Sold Out
» More
Q1 2015

RMTI Guru Trades in Q1 2015

Paul Tudor Jones 25,170 sh (New)
» More
Q2 2015

RMTI Guru Trades in Q2 2015

Paul Tudor Jones 26,035 sh (+3.44%)
» More
» Details

Insider Trades

Latest Guru Trades with RMTI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 13.23
RMTI's Forward P/E is ranked higher than
82% of the 232 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 23.47 vs. RMTI: 13.23 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 9.13
RMTI's P/B is ranked lower than
88% of the 639 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.05 vs. RMTI: 9.13 )
Ranked among companies with meaningful P/B only.
RMTI' s 10-Year P/B Range
Min: 1.73  Med: 7.70 Max: 1425
Current: 9.13
1.73
1425
P/S 9.97
RMTI's P/S is ranked lower than
82% of the 664 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.08 vs. RMTI: 9.97 )
Ranked among companies with meaningful P/S only.
RMTI' s 10-Year P/S Range
Min: 0.47  Med: 2.13 Max: 15.01
Current: 9.97
0.47
15.01
PFCF 66.50
RMTI's PFCF is ranked lower than
67% of the 274 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 40.71 vs. RMTI: 66.50 )
Ranked among companies with meaningful PFCF only.
RMTI' s 10-Year PFCF Range
Min: 25.5  Med: 77.61 Max: 372.33
Current: 66.5
25.5
372.33
POCF 59.85
RMTI's POCF is ranked lower than
78% of the 393 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 27.63 vs. RMTI: 59.85 )
Ranked among companies with meaningful POCF only.
RMTI' s 10-Year POCF Range
Min: 19.62  Med: 42.20 Max: 186.17
Current: 59.85
19.62
186.17
Current Ratio 12.58
RMTI's Current Ratio is ranked higher than
92% of the 619 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.29 vs. RMTI: 12.58 )
Ranked among companies with meaningful Current Ratio only.
RMTI' s 10-Year Current Ratio Range
Min: 0.49  Med: 1.84 Max: 12.58
Current: 12.58
0.49
12.58
Quick Ratio 11.68
RMTI's Quick Ratio is ranked higher than
93% of the 618 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.68 vs. RMTI: 11.68 )
Ranked among companies with meaningful Quick Ratio only.
RMTI' s 10-Year Quick Ratio Range
Min: 0.35  Med: 1.49 Max: 11.68
Current: 11.68
0.35
11.68
Days Inventory 33.78
RMTI's Days Inventory is ranked higher than
87% of the 634 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 111.99 vs. RMTI: 33.78 )
Ranked among companies with meaningful Days Inventory only.
RMTI' s 10-Year Days Inventory Range
Min: 18.25  Med: 24.35 Max: 46.23
Current: 33.78
18.25
46.23
Days Sales Outstanding 26.13
RMTI's Days Sales Outstanding is ranked higher than
87% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 70.80 vs. RMTI: 26.13 )
Ranked among companies with meaningful Days Sales Outstanding only.
RMTI' s 10-Year Days Sales Outstanding Range
Min: 23.3  Med: 41.99 Max: 54.67
Current: 26.13
23.3
54.67

Valuation & Return

vs
industry
vs
history
Price/Net Cash 11.62
RMTI's Price/Net Cash is ranked lower than
55% of the 175 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.86 vs. RMTI: 11.62 )
Ranked among companies with meaningful Price/Net Cash only.
RMTI' s 10-Year Price/Net Cash Range
Min: 4.11  Med: 15.56 Max: 393.8
Current: 11.62
4.11
393.8
Price/Net Current Asset Value 9.58
RMTI's Price/Net Current Asset Value is ranked lower than
63% of the 384 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.25 vs. RMTI: 9.58 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
RMTI' s 10-Year Price/Net Current Asset Value Range
Min: 3.27  Med: 11.16 Max: 315
Current: 9.58
3.27
315
Price/Tangible Book 9.28
RMTI's Price/Tangible Book is ranked lower than
81% of the 590 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.77 vs. RMTI: 9.28 )
Ranked among companies with meaningful Price/Tangible Book only.
RMTI' s 10-Year Price/Tangible Book Range
Min: 2.66  Med: 8.23 Max: 95.01
Current: 9.28
2.66
95.01
Price/Median PS Value 4.69
RMTI's Price/Median PS Value is ranked lower than
96% of the 597 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.26 vs. RMTI: 4.69 )
Ranked among companies with meaningful Price/Median PS Value only.
RMTI' s 10-Year Price/Median PS Value Range
Min: 0.2  Med: 0.93 Max: 6.35
Current: 4.69
0.2
6.35
Earnings Yield (Greenblatt) (%) -2.69
RMTI's Earnings Yield (Greenblatt) (%) is ranked lower than
77% of the 700 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.40 vs. RMTI: -2.69 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
RMTI' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -2.69  Med: 1.10 Max: 2.7
Current: -2.69
-2.69
2.7

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 59 122 82
EPS($) -0.09 0.93 0.32
EPS without NRI($) -0.09 0.93 0.32

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:RWM.Germany,
Rockwell Medical Inc was incorporated in the state of Michigan in 1996. The Company is a fully-integrated biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company manufactures, sells, delivers and distributes hemodialysis concentrates, along with a full line of ancillary products, to customers in the U.S. and abroad. Dialysate concentrates account for over 93% of its revenue and consist of two products known in the industry as acid and bicarbonate and are packaged as liquid or powder. All of its products are manufactured according to Association for the Advancement of Medical Instrumentation and current good manufacturing practices guidelines. Its concentrate products are used in conjunction and are diluted with clean water on-site at the clinic in the dialysis machine, creating dialysate, which works to clean the patient's blood. Its CitraPure concentrate is 100% acetate-free, in contrast to the acetate-based products used for many years. Acetate promotes inflammation so its removal is beneficial to the patient. Dry powder acid concentrate for use with its Dry Acid Mixing System, containing acetic acid, sodium chloride, dextrose and electrolyte additives such as magnesium, potassium, and calcium. It supplies dry acid in 25 gallon cases. Its Dry Acid Concentrate Mixing System is designed for its CitraPure and Dri-Sate Dry Acid product and allows a clinic to mix its acid concentrate on-site. The clinic technician, using a specially designed mixer, adds pre-measured packets of the necessary ingredients to purified water. RenalPure bicarbonate sold in powder form is used mainly in chronic settings. Each clinic mixes bicarbonate on-site as required. SteriLyte bicarbonate is sold in liquid form and is used in acute care settings. It offers ancillary products including blood tubing, fistula needles, specialized custom kits, dressings, cleaning agents, filtration salts and other supplies used by hemodialysis providers. Its largest competitor is U.S. based Fresenius Medical Care NA, which is mainly in the business of operating dialysis clinics, as well as manufacturing and marketing dialysis devices, drugs and supplies. The testing, manufacture and sale of its hemodialysis concentrates and the ancillary products it distribute are subject to regulation by numerous governmental authorities, mainly the FDA and corresponding state and foreign agencies.
» More Articles for RMTI

Headlines

Articles On GuruFocus.com
Brean Capital’s Top Ideas for 2015 Dec 24 2014 
Rockwell Medical Technologies Inc. (RMTI) Chairman, President and CEO, 10% Owner Robert L Chioini se Jan 03 2011 
Rockwell Medical Technologies Inc. (RMTI) Vice President, CFO Thomas E Klema sells 15,000 Shares Jan 03 2011 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) Nov 04 2010 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) Aug 05 2010 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) May 07 2010 
Rockwell Medical Technologies Inc. (RMTI) Chairman, President and CEO, 10% Owner Robert L Chioini se Jan 04 2010 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) Nov 06 2009 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) Aug 10 2009 
Rockwell Medical Technologies Inc. Reports Operating Results (10-Q) May 11 2009 

More From Other Websites
Oppenheimer's Still Buying Rockwell Medical: Channel Checks And Insider Buying Explain Why Aug 21 2015
Rockwell Medical (RMTI) Stock Falls on Morgan Stanley Rating Aug 13 2015
Mid-Morning Market Update: Markets Decline; Kohl's Misses Q2 Views Aug 13 2015
Morgan Stanley: Time To Sell Rockwell Medical Aug 13 2015
Coverage initiated on Rockwell Medical by Morgan Stanley Aug 13 2015
ROCKWELL MEDICAL, INC. Financials Aug 12 2015
Biotech Stock Mailbag: Controversial Stocks Revisited Aug 07 2015
10-Q for Rockwell Medical, Inc. Aug 06 2015
Edited Transcript of RMTI earnings conference call or presentation 4-Aug-15 8:30pm GMT Aug 04 2015
Rockwell Medical reports 2Q loss Aug 04 2015
Rockwell Medical reports 2Q loss Aug 04 2015
Rockwell Medical Inc Earnings Call scheduled for 4:30 pm ET today Aug 04 2015
ROCKWELL MEDICAL, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 04 2015
Rockwell Medical Reports Second Quarter 2015 Results Aug 04 2015
Mesa Laboratories, Inc.: Leads amongst peers with strong fundamentals Aug 04 2015
Q2 2015 Rockwell Medical Inc Earnings Release - After Market Close Aug 04 2015
Rockwell Medical Schedules Second Quarter Earnings Call Jul 27 2015
Mead Johnson Misses Q2 Earnings by a Penny; Guides Low - Analyst Blog Jul 23 2015
LifeSci Capital Initiates Coverage of Rockwell Medical, Inc. Jul 22 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK